GlassScriptPhysician profile
Kristen A Momenee
NPI 1467078261
$3,210.86
in general payments reported to CMS, 2019-2025
31 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $1,253 · 2023: $268 · 2024: $557 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.55 | 2021-2023 | |
| Inspire Medical Systems, INC. | $241.39 | 2025 | Inspire |
| Grt US Holding, INC. | $213.59 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $202.91 | 2021-2024 | Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $199.71 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $177.45 | 2022-2024 | |
| Novo Nordisk INC | $122.09 | 2022 | |
| Kyowa Kirin, INC. | $121.36 | 2024 | |
| Sanofi-Aventis U.S. LLC | $121.15 | 2024 | |
| Insmed, INC. | $118.33 | 2025 | Arikayce |
| Neurocrine Biosciences, INC. | $115.20 | 2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Biodelivery Sciences International, INC. | $91.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.61 | 2021 | |
| Redhill Biopharma INC. | $70.50 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $67.85 | 2022 | |
| Exact Sciences Corporation | $64.27 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $59.35 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $58.89 | 2025 | Acthar |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Depuy Synthes Sales INC. | $39.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $38.34 | 2021 | |
| Scilex Pharmaceuticals INC. | $33.29 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $31.50 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $30.58 | 2022 | |
| Boston Scientific Corporation | $24.60 | 2025 | Wavewriter Alpha Prime 16 |
| Arbor Pharmaceuticals, INC. | $18.30 | 2021 | |
| Fidia Pharma USA INC. | $17.68 | 2022 | |
| Vertos Medical, INC. | $17.20 | 2022 | |
| Tersera Therapeutics LLC | $15.64 | 2021 | |
| Horizon Therapeutics Plc | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Momenee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.